HEMATOLOGY

During a Targeted Oncology case-based roundtable event, Daniel R. Couriel, MD, MS, MBA, discussed how to predict risk of acute graft-vs-host-disease and manage its effects on patients with hematologic malignancies.

Findings from.the phase 1/2 IMAGINE have led the FDA to approve ibrutinib for select pediatric and young adult patients with chronic graft-versus-host disease.

Approval has been granted by the FDA to betibeglogene autotemcel for the treatment of patients with beta-thalassemia based on multiple phase 3 studies.

Pivotal phase 3 result have led the FDA to accept a biologics license applications for omidubicel as treatment of patients with blood cancers requiring allogenic hematopoietic stem cell transplant. The applications has been accepted for priority review.

During a Targeted Oncology case-based roundtable event, Hana F. Safah, MD, discussed risk factors for acute graft-versus-host disease and data supporting treatment for steroid-refractory disease.

Hagop M. Kantarjian, MD, discusses the impact of prominent treatments in acute lymphoblastic leukemia.

Following positive phase 1 study results for eltanexor monotherapy in patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndrome, the FDA has granted the drug fast track status.

According to an analysis of 161 trials, patients and physicians should be encouraged to use phase 1 trials for meaningful therapy.

The FDA has granted fast track designation to abelacimab for the treatment of thrombosis associated with cancer. The agent is being assessed in 2 phase 3 clinical trials.

Gunther Koehne, MD, PhD, discusses his hopes for future advances for patients with hematologic malignancies.

Michael R. Bishop, MD, discussed a patient with graft-versus-host disease who first underwent a myeloablative conditioning regimen and peripheral blood stem-cell matched hematopoietic cell transplant as treatment.

During a Targeted Oncology case-based roundtable event, Nelson Jen An Chao, MD, discussed risk management and treatment of patients with steroid-refractory acute graft-versus-host-disease as well as chronic graft-versus-host disease.

The excitement surrounding advances and improved outcomes in very difficult-to-treat diseases is palpable. Yet the complexities of these therapies also bring their own complications.

Jeffrey S. Miller, MD, discusses the findings of a study of the Tri-Specific Killer Engager platform for the activation of natural killer cells for the treatment of refractory acute myeloid leukemia and other cancers.

The probability of minimal residual disease negativity and complete remission in patients who received hyper-CVAD with blinatumomab and inotuzumab is higher compared with hyper-CVAD and blinatumomab alone.

During a Targeted Oncology case-based roundtable event, Pashna N. Munshi, MD, discussed the case of a patient who developed maculopapular rash 22 days following hematopoietic stem cell transplantion.

During a case-based roundtable event, Matthew McKinney, MD, discussed data supporting the use of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA has granted approval to azacitidine for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia following positive phase 2 research.

Manali Kamdar, MD, MBBS, discusses the background on a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell non-Hodgkin’s lymphoma.

The FDA allows for an investigational new drug application for the start of the BEXMAB study of bexmarilimab plus standard of care therapy in various hematologic malignancies.

In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed the evolving role of stem cell transplant in hematologic malignancies as CAR T-cell therapies begin to reshape treatment landscapes.

As these new techniques evolve and we adjust conditioning regimens, induction timing and dosing levels, as well as introducing different drug combinations, we are very hopeful that we will continue to see improved outcomes for hematologic malignancies, says Guenther Koehne, MD, PhD.

Patients with chronic graft-versus-host disease who received a full series of the SARS-CoV-2 vaccine showed varied immune responses, regardless of their baseline characteristics.

The primary end point has been met in the phase 3 ADVANCE trial which evaluated the efficacy and safety of efgartigimod alfa-fcab in patients with thrombocytopenia.

Total body irradiation followed by graft-versus-host disease prophylaxis is considered a feasible and effective regimen for both adult and pediatric patients, according to phase 2 study results.